Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SOM-230

Known as: SOM 230, SOM230 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pasireotide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Review
2010
Review
2010
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
Background  The discovery of somatostatin (SST) and the synthesis of a variety of analogues constituted a major therapeutic… Expand
Highly Cited
2009
Highly Cited
2009
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
CONTEXT There is currently no medical therapy for Cushing's disease that targets the pituitary adenoma. Availability of such a… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Review
2008
Review
2008
Pasireotide (SOM230): Development, mechanism of action and potential applications
  • H. Schmid
  • Molecular and Cellular Endocrinology
  • 2008
    • Corpus ID: 8975340
Pasireotide (SOM230) is a multi-receptor ligand somatostatin analogue with high binding affinity for somatostatin receptor… Expand
Highly Cited
2006
Highly Cited
2006
The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
CONTEXT There is no tumor-directed medical therapy available for Cushing's disease. OBJECTIVE The objective was to determine… Expand
Highly Cited
2005
Highly Cited
2005
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.
In a series of human corticotroph adenomas, we recently found predominant mRNA expression of somatostatin (SS) receptor subtype 5… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2005
Highly Cited
2005
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
OBJECTIVE Currently, there is no effective medical treatment for patients with pituitary-dependent Cushing's disease. A novel… Expand
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Highly Cited
2004
Highly Cited
2004
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
To determine the inhibitory profile of the novel somatostatin (SRIF) analog SOM230 with broad SRIF receptor binding, we compared… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2004
Highly Cited
2004
Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors
Functional gastroenteropancreatic tumors express all 5 somatostatin receptor subtypes (sst) in different quantities. Octreotide… Expand
  • table 1
  • figure 1
  • table 2
Highly Cited
2002
Highly Cited
2002
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
OBJECTIVE The aim of the present study was to identify a small, metabolically stable somatotropin release inhibiting factor (SRIF… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE